NCT04745273

Brief Summary

In the postoperative period; pain, nausea, and vomiting are undesirable side effects that reduce the patient's comfort and may lead to various complications. Ondansetron is frequently used as an antiemetic and tramadol hydrochloride is used for postoperative analgesia in laparoscopic cholecystectomy. However, some studies have reported that there is a drug interaction between these two drugs and they reduce each other's effects, thus requiring more analgesics in the postoperative period. The aim of this study is; To evaluate whether ondansetron reduces the analgesic efficacy of tramadol hydrochloride in laparoscopic cholecystectomies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Sep 2020

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 2, 2020

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 31, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 9, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 25, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 25, 2021

Completed
Last Updated

November 8, 2022

Status Verified

November 1, 2022

Enrollment Period

10 months

First QC Date

January 31, 2021

Last Update Submit

November 6, 2022

Conditions

Keywords

tramadolondansetron

Outcome Measures

Primary Outcomes (1)

  • Interaction

    The hypothesis of this study is that if ondanstron is given together with tramadol peroperatively, tramadol consumption is increase postoperatively due to tramadol ondansetron interaction. The primary outcome measure is consumption of tramadol postoperatively for 24 hours.

    24 hours

Study Arms (2)

Ondansetron

ACTIVE COMPARATOR

Participants will receive Kemoset 4 mg iv intraoperatively

Drug: Ondansetron 4 MG (Kemoset 4mg)

Salin solution

PLACEBO COMPARATOR

Participants will receive Salin solution 2ml (iv) intraoperatively

Other: Salin solution

Interventions

Ondansetron 4mg (iv) will administer to participants

Also known as: Kemoset
Ondansetron

Salin solution 2ml (iv) will administer to participants

Salin solution

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients over the age of 18, ASA I-II, undergoing laparoscopic cholecystectomy

You may not qualify if:

  • Patients under 18 years of age
  • Patients with known allergies to the drugs to be used
  • Pregnant and breastfeeding mothers
  • Patients who received antiemetic or cortisone within 24 hours before surgery
  • Patients with mental illness or epilepsy
  • Patients with alcohol or substance abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Acibadem Kozyatagi Hastanesi

Istanbul, (_34742__) ______, Turkey (Türkiye)

Location

Related Publications (1)

  • Bilgen S, Erdogan Ari D, Ozveri E. The Effect of Ondansetron on the Analgesic Efficacy of Tramadol in Patients Undergoing Laparoscopic Cholecystectomy. Int J Clin Pract. 2022 Mar 8;2022:7387600. doi: 10.1155/2022/7387600. eCollection 2022.

MeSH Terms

Interventions

Ondansetron

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCarbazolesIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds, 3-Ring

Study Officials

  • Sevgi Bilgen, Assoc. Prof.

    Anethesiologist

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

January 31, 2021

First Posted

February 9, 2021

Study Start

September 2, 2020

Primary Completion

June 25, 2021

Study Completion

June 25, 2021

Last Updated

November 8, 2022

Record last verified: 2022-11

Locations